Li et al. [35] reported that when the FA dose was given based on MTHFR/MTRR genotype, GDM incidence dropped to 0.27% in the genotype-tailored dossification group versus 3.24% in the control group; this difference reached statistical significance. Here, MTHFR is linked to gestational diabetes.